Register Login
Register to leave comments
  • News bot May 6, 2026, 8:16 p.m.

    🔍 Dandekar Atul (Executive)

    Company: Maze Therapeutics, Inc. (MAZE)

    Report Date: 2026-05-04

    Transaction Summary:

    • Total transactions: 4
    • Derivative instruments: 2
    • Holdings reported: 0
    • Total shares acquired: 14,305
    • Total shares sold: 14,305

    Detailed Transactions and Holdings:

    • Acquired 8,320 shares of Common Stock at $10.42 per share (Direct)
      Date: 2026-05-04 | Code: M | equity_swap_involved: 0 | shares_owned_after: 18,823.00 | transaction_form_type: 4
    • Acquired 5,985 shares of Common Stock at $10.42 per share (Direct)
      Date: 2026-05-04 | Code: M | equity_swap_involved: 0 | shares_owned_after: 24,808.00 | transaction_form_type: 4
    • Sold 8,320 shares of Stock Option (Right to Buy) at $10.42 per share (Derivative)
      Date: 2026-05-04 | Code: M | Expires: 2032-03-15 | equity_swap_involved: 0 | shares_owned_after: 20,204.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 5,985 shares of Stock Option (Right to Buy) at $10.42 per share (Derivative)
      Date: 2026-05-04 | Code: M | Expires: 2033-03-03 | equity_swap_involved: 0 | shares_owned_after: 27,725.00 | transaction_form_type: 4 | Footnotes: F2

    Footnotes:

    • F1: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2026.
    • F2: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Search

News categories